XTALPI (02228) surged over 8% again, closing up 6.66% at HK$12.97 with trading volume reaching HK$1.223 billion as of press time.

On the news front, XTALPI recently announced the signing of a cooperation letter of intent with Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. According to the cooperation agreement, Hangzhou Bio-Sincerity has commissioned XTALPI to conduct new drug development work using its "AI + robotics" platform, while XTALPI will commission Hangzhou Bio-Sincerity to undertake pharmaceutical research and other R&D activities.

The two parties also plan to jointly advance the development and incubation of innovative drug pipelines across multiple disease areas including pain, narcolepsy, oncology, autoimmune diseases, and ophthalmology, targeting unmet clinical needs through XTALPI's AI drug discovery platform. They will explore the establishment of a joint venture company when appropriate to pursue broader commercial cooperation opportunities.

Notably, on September 24, XTALPI Chairman Wen Shuhao and CEO Ma Jian visited China Merchants Group's Shenzhen headquarters for in-depth meetings with China Merchants Group Chairman Miao Jianmin and General Manager Shi Dai. This visit aimed to seek strategic synergies, with XTALPI hoping to use this opportunity as a catalyst for industry application-oriented collaboration with China Merchants Group and China Merchants Innovation & Technology in areas such as accelerating new drug development, novel materials discovery, and chemical automation, leveraging resource advantages to achieve win-win development.